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Abstract
The vast landscape of environmental chemicals has motivated the need for alternative methods to traditional whole-animal
bioassays in toxicity testing. Embryonic stem (ES) cells provide an in vitro model of embryonic development and an
alternative method for assessing developmental toxicity. Here, we evaluated 309 environmental chemicals, mostly food-use
pesticides, from the ToxCast
TM chemical library using a mouse ES cell platform. ES cells were cultured in the absence of
pluripotency factors to promote spontaneous differentiation and in the presence of DMSO-solubilized chemicals at different
concentrations to test the effects of exposure on differentiation and cytotoxicity. Cardiomyocyte differentiation (a,b myosin
heavy chain; MYH6/MYH7) and cytotoxicity (DRAQ5
TM/Sapphire700
TM) were measured by In-Cell Western
TM analysis. Half-
maximal activity concentration (AC50) values for differentiation and cytotoxicity endpoints were determined, with 18% of
the chemical library showing significant activity on either endpoint. Mining these effects against the ToxCast Phase I assays
(,500) revealed significant associations for a subset of chemicals (26) that perturbed transcription-based activities and
impaired ES cell differentiation. Increased transcriptional activity of several critical developmental genes including BMPR2,
PAX6 and OCT1 were strongly associated with decreased ES cell differentiation. Multiple genes involved in reactive oxygen
species signaling pathways (NRF2, ABCG2, GSTA2, HIF1A) were strongly associated with decreased ES cell differentiation as
well. A multivariate model built from these data revealed alterations in ABCG2 transporter was a strong predictor of
impaired ES cell differentiation. Taken together, these results provide an initial characterization of metabolic and regulatory
pathways by which some environmental chemicals may act to disrupt ES cell growth and differentiation.
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Introduction
Over 82,000 chemicals are currently in commerce or in the
environment, yet little is known about their potential toxicity to
humans [1]. The data gaps between the environmental chemical
landscape and chemical toxicity information is largely due to the
low-throughput nature of traditional toxicity testing that relies on
whole-animal studies and relatively high-dose exposure. These tests
can be slow, costly, and ultimately provide only a gross estimation of
the human response to chemicals. In an effort to bridge the gap
between chemical space and toxicity information, the National
Research Council released a report calling for a paradigm shift in
toxicity testing [1]. Four primary objectives are outlined in
‘‘Toxicity Testing in the 21
st Century: A Vision and a Strategy’’:
1) broad assessment of chemicals, 2) faster, more cost-effective
approaches, 3) reduce animal use, and 4) reflect mechanism and
dose in risk assessment [1]. Towards this end, in vitro and in silico
methods are being implemented and evaluated with respect to their
predictivity and relevance to in vivo toxicity pathways.
In vitro assays provide multiple benefits for pathways-based risk
assessment. First, in vitro assays are amenable to high-throughput
formats and thus can be scaled to the evaluation of thousands of
chemicals across diverse cellular responses in a relatively short
amount of time. Second, chemicals can be tested across a wide
range of concentrations allowing the half-maximal activity
concentration (AC50) to be calculated and considered in the
context of environmentally realistic exposures. Third, human in
vitro model systems provide a glimpse into the potential human
cellular responses to chemical insult and may illuminate species-
specific differences in toxicity. Finally, in vitro approaches allow us
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e18540to interrogate the mechanism of chemical toxicity and assess
pathway-based chemical perturbation by employing biochemical,
molecular, and genetic techniques.
The US Environmental Protection Agency (EPA), in collabo-
ration with the National Institutes of Environmental Health
Sciences (NIEHS), the National Chemical Genomics Center
(NCGC) and the Food and Drug Administration (FDA) are
working together to establish alternative chemical testing methods
that will characterize toxicity pathways [2]. Many of the EPA’s
ToxCast
TM chemical library of 309 unique compounds, mostly
well-characterized food-use pesticides, have been previously
tested under the traditional in vivo toxicology testing paradigm.
Therefore, these data-rich pesticides have been subjected to a
variety of whole-animal tests including sub-chronic and chronic
rodent bioassays, developmental toxicity, and multi-generation
reproductive studies representing over 30 years of in vivo toxicity
experiments assembled into a searchable database, ToxRefDB
[3,4,5]. In Phase I of ToxCast, all 309 chemicals were tested over a
wide-range of concentrations across a collection of ,500 bioassays
[6,7,8]. These include cell-free biochemical, cell-based activity,
and embryonic stem cell screening platforms (described here). The
power of ToxRefDB and ToxCast is the ability to develop
predictive signatures of toxicity via in silico modeling, with the
ultimate goal of using predictive signatures to interrogate the vast
chemical space which currently lacks toxicity profiles. Chemicals
that perturb toxicity pathways could then be prioritized for more
in-depth testing.
Embryonic stem (ES) cells are potentially informative in the
context of toxicity testing due to their reliance on many key
pathways in morphogenesis and differentiation. ES cells are
isolated from the inner cell mass of blastula-stage embryos and
retain the ability to differentiate into all three germ layers of the
embryo proper when cultured in the absence of pluripotent
factors. Components of the three primary germ layers (ectoderm,
endoderm, mesoderm) interact to contribute to all cell lineages of
the adult mouse [9,10]. Pluripotent ES cells have the ability to self-
renew indefinitely when maintained in pluripotent culture
conditions [11]. Given the dynamic potential of ES cells, this
platform harbors key signaling pathways and biological networks
that govern their pluripotency and/or differentiation. In addition,
ES cells have been shown to mimic many aspects of early
embryonic development [12] and are amenable to systems-level
analysis utilizing high-throughput screening (HTS) and high-
content screening (HCS) methods.
Taking advantage of the developmental potential of ES cells, the
embryonic stem cell test (EST) was established over a decade ago
as an alternative method for assessing chemical embryotoxicity
[13]. The EST uses three separate endpoints (cardiomyocyte
differentiation, ES cell viability, fibroblast viability) in a prediction
model to evaluate chemical toxicity and affords up to 78%
accuracy [14,15,16]. In spite of this predictive attribute, there are
drawbacks to the EST assay: 1) subjective nature of measuring
cardiomyocyte differentiation based on qualitative observations, 2)
viability and differentiation measures are collected from separate
cultures, and 3) limited throughput. Others have expanded on the
original foundation of the EST using transcriptomics in mouse ES
cells or metabolomics of pluripotent human ES cells to identify
developmental toxicants [17,18].
Here, we utilize a modification to deliver a high-throughput,
sensitive method for quantitatively measuring cytotoxicity and
cardiomyocyte differentiation. Furthermore, we have introduced
this platform to the ToxCast portfolio for in vitro profiling of 309
environmental chemical compounds across ,500 different assays.
This confers a unique platform to the ToxCast portfolio for
chemical screening as a complex cell culture system that mimics
early mammalian embryonic development and maintains relevant
signaling networks required for primary germ layer formation. We
hypothesize that the ES cell assay may identify toxicity pathways
in ES cell differentiation that are predictive of developmental
activity of chemicals. Towards this end, concentration-response
relationships for 309 environmental chemicals were measured in
the ES cell assay. A subset of 56 of these chemicals showed a
statistically significant response across one or more of the following
four parameters: increased cytotoxicity, decreased cytotoxicity,
decreased differentiation,m and increased differentiation. For each
chemical-by-endpoint combination showing significant activity, we
calculate an AC50 (concentration at which activity is 50% of
maximal change). This report describes the results of these
experiments and provides the first computational (in silico) model of
a toxicity-related pathway underlying ES-based developmental
bioactivity across the chemical library.
Materials and Methods
ES cell maintenance and differentiation
J1 male murine ES cells from the 129S4/SvJae strain were
obtained from ATCC (www.atcc.org) and maintained according
to their recommendations for propagation and subculturing
(ATCC, SCRC-1010
TM). In brief, J1 cells were cultured on
Mitomycin C-treated primary mouse embryo fibroblasts (MEFs,
Millipore, Cat. No. PMEF-CF) on 0.1% gelatin (Millipore, Cat.
No. SF008) in ES cell media containing Knockout DMEM
(Invitrogen, Cat. No. 10829), 15% ES cell-qualified fetal bovine
serum (Invitrogen, Cat. No. 10439), 2 mM GlutaMAX (Invitro-
gen, Cat. No. 35050), 0.1 mM non-essential amino acids (Invitro-
gen, Cat. No. 11140), 50 U/50 ug/mL Pen/Strep (Invitrogen,
Cat. No. 15140), b-mercaptoethanol (Gibco, Cat. No. 21985), and
1000 U/mL mouse leukemia inhibitory factor (mLIF, Millipore,
Cat. No. ESG1107). Prior to evaluating the effects of chemicals,
MEFs were removed from cultures prior to an experiment by
passing ES cells onto 0.1% gelatin-coated flasks in MEF-
conditioned media with mLIF to maintain pluripotency. On
day 0, pluripotent MEF-depleted ES cells were collected and
cell counts were determined with a NucleoCounterH NC-100
(ChemoMetec). Cells were seeded at a density of 1000 cells/well
onto 0.1% gelatin-coated 96-well plates (Costar, Cat. No. 3596) in
ES cell media without mLIF (differentiation conditions) and
allowed to adhere to the plates overnight. ToxCast chemicals were
introduced on day 1 and subsequently refreshed on days 6–8.
Chemical Library
This study used the ToxCast Phase I, version 1 chemical
library which contains 320 total chemicals with the following
breakdown: 309 unique chemical structures, 5 independently
sourced duplicates, and 3 triplicates that serve as plating
replicates for internal quality control [6]. The majority of these
chemicals had bioassay data available from ToxRefDB guideline
animal studies (rat, mouse, rabbit), 97.5% are soluble in DMSO,
90% have a molecular weight between 250–1000, and 98.1% are
commercially available with .90% purity. Information on the
chemical library is publically available (http://www.epa.gov/
NCCT/dsstox/sdf_toxcst.html). Chemical procurement and
stock preparation was outsourced to BioFocus DPI (South San
Francisco, CA) and certificates of analysis were provided with
plated chemicals. Plated chemicals were subjected to a QC check
and the results are publically available (http://www.epa.gov/
ncct/toxcast). Due to the effects of DMSO on the ES cells and
the maximum concentrations of chemicals plated by BioFocus
Chemical Activity in an ES Cell Platform
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concentration evaluated.
Cytotoxicity and Differentiation Measurements
In-Cell Western
TM (Li-Cor Biosciences) assays were initiated on
cell culture day 9 and performed according to the manufacturer’s
protocol. In brief, cells were fixed in the assay plate, incubated
with primary antibody, secondary antibody, and DNA/cell stains,
then assay plates were scanned on a Li-Cor OdysseyH Infrared
Imaging System. This system allows for detection of two endpoints
in each well by measuring signal intensity in two infrared channels.
Cardiomyocyte differentiation was measured using a primary
mouse antibody that recognizes a,b cardiac Myosin Heavy Chain
(MYH6/MYH7)(Abcam, Cat. No. ab15; 1:1000). Cells were
incubated in primary antibody overnight at 4uC with gentle
agitation. A goat a-mouse secondary antibody conjugated to
IRDyeH 800CW (Li-Cor, Cat. No. 926-32210; 1:2000) was
detected at 800 nm. Cytotoxicity was assessed using Sapphir-
e700
TM (1:2000) relative cell and DRAQ5
TM (1:16,000) DNA
stains (Li-Cor, Cat. No. 948-40022) were detected at 680 nm. Cell
stain and MYH6/MYH7 intensities are corrected for background
signal using intensity values from control wells, which were
incubated without primary antibody or cell stains. Quality control
checks were performed by visual inspection of the plate images
and removal of obvious outlier data due to technical issues.
MYH6/MYH7 signal was normalized to relative cell number
(cytotoxicity) by dividing MYH6/MYH7 intensity by Sapphir-
e700
TM/DRAQ5
TM intensity from the same wells. Cytotoxicity
and cytotoxicity-corrected cardiomyocyte differentiation values
were made relative to the zero dose control.
Dose-response curves and AC50 calculations
Relative cytotoxicity and cardiomyocyte differentiation values
were analyzed to detect statistically significant concentration-
dependent behavior. Concentration-response analysis used soft-
ware developed in-house in the R language, run using R version
2.8.1 (software available upon request). First, the variation of 0-
concentration control (i.e. DMSO vehicle) values was assessed for
all experiments by calculation of the mean and standard deviation.
Then, a cutoff was established by taking the mean of the 0-
concentration controls +/22 standard deviations. Values that fell
outside the cutoff were considered different from control. If all
values for a treatment fell within the established 0-concentration
control variation, the treatment was said to have no effect, a curve
fit was not performed, and a default AC50 value of 1 M was
assigned to that combination. If there was a significant change
from baseline, the concentration-response data were fit to a four-
parameter Hill curve using nonlinear least-squares regression. The
AC50 was then assigned as the dose along the curve that produced
a 50% change from the mean of the 0-concentration control.
Separate analyses were performed for curves that exhibited an
upward trend versus a downward trend. For data that exhibited a
downward trend, the 0-concentration control value of 1 was set at
the top (100%) and complete reduction of signal was the bottom
(0%). For the upward trend analysis, data were adjusted by
subtracting 1 which made the 0-concentration equal to the bottom
(0%). A 100% increase from the 0-concentration control
represented the top and was set to 1 (100%). ACF were calculated
using the AC50 values in the context of the following equation
(Eq.1), where ACF is the concentration at which there was F
percent change in activity relative to the 0-concentration. F is the
chosen percentage of change to be evaluated and Hillslope is the
calculated slope of the non-linear regression curve fit from the R
analysis:
ACF ~AC50X
F
100{F
   1=Hillslope
  
ð1Þ
Heatmaps were produced with Partek Genomic Suite 6.4 software
(Partek, Inc., St. Louis MO). Unsupervised, two-dimensional
hierarchical clustering was performed using Euclidean distance for
measure and Ward’s method for linkage analysis.
Predictive models
Data (in the form of AC50 values) for the ES assays were
analyzed by comparison with a large number of other in vitro assays
measured in the same chemical library. These comprise the
ToxCast data set described elsewhere [3,4,5,6,7,19]. The complete
data set consists of a matrix of 309 chemicals (rows) by 548 assays
(columns). The values are AC50’s for the chemical-assay
combinations, with a default value of 1 M in cases where no
statistically significant chemical-assay activity was observed.
Pathway, process and disease-based perturbation scores (PS) were
constructed by mapping assays to genes and then to collections of
genes in pathways from KEGG, Ingenuity, Pathway Commons,
Gene Ontology (GO) and OMIM. In brief, a chemical-pathway
PS corresponds to the minimum AC50 for any assay for that
chemical mapping to the pathway. The PS form additional
columns in the data matrix. The details for calculating PS for a
chemical-pathway combination is described elsewhere [6].
In addition to the ToxCast in vitro assays, we also have in vivo
animal-based endpoints for a majority of these chemicals (from
chronic, cancer, reproductive developmental toxicity studies),
extracted from the EPA Toxicity Reference Database (ToxRefDB,
http://www.epa.gov/NCCT/toxrefdb/) [3,4,5]. These data are
quantified as LEL (lowest effective level) values which give the
lowest dose at which an endpoint was observed, and form extra
columns to the data matrix.
We calculated univariate statistical associations between the ES
cell data and both the ToxCast in vitro assays and ToxRefDB in vivo
endpoints. Two statistical tests were used. In the first, the data
matrix was dichotomized so that if activity was seen at any
concentration (assays) or dose (endpoints), a value of 1 was
assigned to the chemical- assay (endpoint) pair. Otherwise a value
of 0 was assigned. Next, one assay was selected as the input
(predictor variable) and another assay (or endpoint) as the output
(predicted variable). A 262 contingency table was created with
value TP (true positive, number of chemicals for which the input
and output were both positive), FP (false positive, number of
chemicals for which the input was positive and output negative),
FN (false negative, number of chemicals for which the input was
negative and the output positive) and TN (true negative, both
input and output negative). The significance of association was
tested using a Fisher’s exact test. In the second statistical method,
the input assay AC50 values were log transformed and scaled:
scoreassayi chemicalj ðÞ ~{log10 AC50assayi chemicalj ðÞ  
10
6
  
ð2Þ
This scaling yields a value of zero for inactive chemical-assay
combinations. The output variable is dichotomized as before. We
then perform a t-test comparing the score distribution for the
output-positive vs. output-negative chemicals.
We also constructed multivariate models to predict activity of
chemicals in the ES assays from data for multiple other in vitro
assays. For this analysis, the original data matrix was log-
transformed (Eq. 2). The model is of the form:
Chemical Activity in an ES Cell Platform
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X N max
assayi~1
di|
scorei chemicalj ðÞ
ð3Þ
where if dis 1, then assay i is included, otherwise it is not. If the
model score for chemical i is .0, the chemical is predicted to be
active in the output assay or endpoint, otherwise it is predicted to
be inactive. Assays are added to the sum in a stepwise fashion, so
that the one with the most significant univariate association (using
either of the statistical tests described above) is added first, the
second most significant is added next and so on. Model
performance is evaluated using a 262 contingency table as
described above where the true activity vector for the output assay
is compared with the predicted activity vector. The model is
implemented using a k-fold cross validation algorithm in which the
data is divided into training (80%) and test (20%) portions and
optimal values of Nmax and Cutoff are found which maximize the
area under the curve (AUC) of the Receiver Operator Charac-
teristic (ROC) curve. In addition to the AUC and Fisher’s exact p-
value, we also calculate the sensitivity, specificity, balanced
accuracy (BA, average of sensitivity and specificity) and other
metrics. The algorithm is implemented in R and is available upon
request (‘‘linmod.R’’ (NCCT, US EPA)). ROC curves are built to
predict the ES assays as outputs and used the ToxCast assays and
pathway perturbation scores as inputs.
Results
Mouse ES cell assay
We evaluated the effects of 309 chemicals in duplicate across four
concentrations on cardiomyocyte differentiation and cell number
in a ten-day, high-throughput mouse ES cell adherent cell
differentiation and cytotoxicity assay (Figure 1). Using a 96-well
format, we tested eight chemicals per plate in duplicate, one per
row,at concentrationsrangingfrom 0.0125 to 12.5 mM (Figure 2A).
Curves generated from the concentration-responses of the chemical
library indicate that under the conditions employed here, the assay
was responsive to a subset of 309 chemicals. For example,
Rimsulfuron had no measurable biological activity in the ES cell
system (Figure 2B). Spiroxamine was a potent inhibitor of
cardiomyocyte differentiation, yet had no significant effect on
cytotoxicity(Figure 2B).Otherchemicals,suchasPaclobutrazoland
Picaridin, began to show effects on differentiation, but not enough
to calculate an AC50 (Figure 2B). A small number of chemicals
(n=5) produced effects on cytotoxicity or differentiation that did
notresemble traditional upwardordownward curves. Instead,these
chemicals generated a U-shaped or inverse U-shaped trend. All 320
concentration response curves are provided (Figure S1). Overall,
these results show the assay is capable of detecting chemical effects
on number and differentiation of ES cells.
Eighteen percent of the chemical library (56/309 chemicals)
produced effects permitting AC50 values to be calculated for the
ES cell assay (Table 1). Of the AC50 values calculated, 25%
(18/69) exhibited chemical potencies below one micromole. The
most potent chemical in our cytotoxicity assay was Captafol
(AC50=0.017 mM), while the chemical with the most pronounced
effect on decreased cardiomyocyte differentiation was Rotenone
(AC50=0.13 mM) (Table 1). Thirty-two percent of AC50 values
(22/69) were greater than 10 mM. The least potent chemical
of those which produced a 50% change in the cytotoxicity
and differentiation assays was Difenoconazole (AC50(Cytotoxici-
ty)=17mM, AC50(Differentiation)=18mM) (Table 1). Most AC50
values were calculated from decreased cell number and/or
decreased differentiation (82.6%, 57/69). However, four chemicals
increased differentiation and eight chemicals increased cell
number in our assay. Dicrotophos increased cardiomyocyte
differentiation (AC50=0.45 mM). Likewise, Mancozeb increased
cell number with similar potency (AC50=0.43 mM).
The chemical library included three chemicals run in triplicate to
assess assay replicability. The coefficient of variation for the replicates
on both cytotoxicity and differentiation measurements at each dose
including vehicle controls was less than 22%, indicating good
replicability. In addition, a global view of the chemical library
demonstrated varied activity of chemicals across concentration
(Figure 3). The most potent chemicals killed all of the cells as
indicated by the white block in the top left corner of the heat map
(Figure 3). The highest concentrations clustered together while the
vehicle dose formed a separate cluster indicating their similar activity
profiles (Figure 3A). Averages for cytotoxicity and differentiation
measurements clustered the doses in order from lowest concentration
to highest concentration for both parameters (Figure 3B).
Univariate associations between ES cell assay endpoints
and ToxCast assays
The ToxCast data set includes over 500 assays run using cell-
free and cell-based format in nine separate technologies. The cell-
based assays use a variety of primary cell types and cell lines [6].
Data from all 309 chemicals across these assays (as well as the
derived pathway-based perturbation scores and whole animal
toxicity endpoints) was used to build univariate and multivariate
models using the ES cell assay as both input and output variables.
We used the ES cell endpoints as inputs to mine the assay space
for significant correlations (Figure 4). The ES cell cytotoxicity
endpoint (decreased relative cell number) associated with 98
endpoints in the ToxCast assay suite (p#0.1). The majority of
endpointsthatcorrelated withEScellcytotoxicitywerefromhuman
cell-based platforms that reveal disruption of cell-cell signaling (e.g.
BioSeek) and cellular features (e.g. Cellumen) (Figure 4). Many of
the former endpoints represented immune system responses or
components such as cytokines (Figure S2). The latter endpoints that
associated significantly with ES cell cytotoxicity were general
measures of cytotoxicity such as apoptosis or DNA damage (Figure
S2), indicating the cell number endpoint in the ES cell assay was
consistent with other cell-based cytotoxicity endpoints. In addition,
ES cell cytotoxicity had significant correlations to mouse, rat and
Figure 1. ES cell assay overview. ES cells are seeded onto gelatin-
coated 96-well plates at Day 0 in the absence of pluripotent factors.
Eight chemicals (color outlined circles) are introduced on Day 1 at four
concentrations (yellowRred; 0.0125, 0.125, 1.25, 12.5 uM) and are
subsequently refreshed on Days 6–8. In-Cell Western
TM analysis is
initiated on Day 9 to assess differentiation (MYH6/MYH7) and
cytotoxicity (DRAQ5/Sapphire700). Vehicle (grey outlined circles) and
antibody controls (black outlined wells, Day 9–10) are included on each
plate.
doi:10.1371/journal.pone.0018540.g001
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pubertal development in multigenerational rat studies and cranial
malformations in prenatal rabbit studies.
Decreased cardiomyocyte differentiation associated with slightly
fewer endpoints than did cytotoxicity (k=88, p#0.1) (Figure 4).
Again, more than 80% of associations were to the aforementioned
Figure 2. Dose-response curves generated for cytotoxicity and differentiation. Images of experimental plate show cell number and
differentiation signal for chemicals 17–24 across the concentration range tested (A). Dose-response curves for six chemicals from the above plate as
well as AC50 values are shown (B).
doi:10.1371/journal.pone.0018540.g002
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differentiation endpoint associated with mouse and rat ToxRefDB
in vivo endpoints, including renal defects in developmental rat
studies. However, unlike the increased cytotoxicity and decreased
differentiation endpoints, the decreased cytotoxicity and increased
differentiation endpoints had limited univariate associations across
the ToxCast assay space (cytotoxicity decrease: k=16, p#0.1;
differentiation increase: k=1, p#0.1).
Univariate associations between ToxCast assays and ES
cell endpoints
Using the reversed strategy, the ToxCast assay targets (k.500)
were used as inputs to look for associations with the ES cell
endpoints (k=4). One hundred seven ToxCast assay endpoints
associated with ES cell cytotoxicity. All but two of these associations
werefrom cell-based assay platforms (Figure 4).A similar number of
ToxCast assay targets associated with ES cell differentiation
(k=112). We found 21 transcriptional activity-based endpoints
from two different platforms (Attagene, CellzDirect) [6,19] that
correlated with ES cell differentiation. When we looked deeper into
the reporter gene responses, a striking finding emergedthat many of
these responses representedcritical developmental pathways (Figure
S2). For example, Bone morphogenetic protein receptor type II
(BMPR2) showed a significant association with decreased cardio-
myocyte differentiation in the ES cell assay (p=0.01). In mice,
Bmpr2 is required for normal mesoderm development [20].
Likewise, Paired box gene 6 (PAX6) had a significant association
with an inhibition on ES cell differentiation (p=0.12). Pax6
mutations in mice produce a range of phenotypes including eye,
craniofacialandbraindefects[21].Increasedtranscriptionalactivity
of OCT1 was significantly associated with decreased cardiomyocyte
differentiation (p=0.03). Oct1 has recently been shown to be
required for normal trophoblast development in mice [22]. In
addition to associations with developmentally regulated genes,
multiple assay endpoints present in the oxidative stress signaling
pathway were strongly associated with decreased ES cell differen-
tiation. For example, increased transcriptional activity of NRF2
(p=0.008), a classic oxidative stress-responsive gene [23,24], was
associated with decreased cardiomyocyte differentiation. Likewise,
JUN (p=0.008), ABCG2 (p=0.001), GSTA2 (p=0.05), and HIF1A
(p=0.06) correlated with decreased ES cell differentiation. Finally,
increased transcriptional activity of EGR1 (p=0.04) and OCT1
(p=0.03), which have been shown to play a role in oxidative stress
pathways [25,26,27], are highly correlated with decreased ES cell
Table 1. AC50 values calculated and arranged according to potency.
Cytotoxicity Differentiation Cytotoxicity Differentiation
Chemical Decrease Increase Increase Decrease Chemical Decrease Increase Increase Decrease
Rotenone 0.20 0.13 Thiram 0.11
Nitrapyrin 0.081 0.18 Fluazinam 0.22
Trifloxystrobin 0.72 0.39 Cyromazine 1.3
Fluoxastrobin 0.80 0.99 Dicamba 1.4
Niclosamide 0.32 1.0 Diquat dibromide 2.1
Propargite 1.5 1.2 Imazamox 2.5
Maleic hydrazide 0.39 1.3 Naled 2.5
IPBC 2.2 1.4 Phosalone 2.7
Azoxystrobin 1.7 5.0 Milbemectin 2.9 2.7
Etoxazole 14 6.6 Benomyl 3.0
Folpet 0.65 10 Abamectin 3.4
Fentin 1.3 12 Mepiquat chloride 5.4
Thidiazuron 12 15 TCMTB 6
Difenoconazole 17 18 Fludioxonil 11
Spiroxamine 0.47 Maneb 12
Diniconazole 1.2 Buprofezin 17
Triflumizole 5.8 Dicrotophos 0.45
Methoxyfenozide 6.3 Diuron 9.7
Triadimenol 8.2 Permethrin 15
Propiconazole 9 Mancozeb 0.43
Triclosan 10 Captan 4.6
Endosulfan 11 Cyazofamid 5.1
Imazalil 11 Bensulide 9.1
Prochloraz 12 Oxadiazon 12
Bifenazate 15 Dicofol 13
Butafenacil 16 Profenofos 14
Captafol 0.017 Fluroxypyr-meptyl 15
Acetamiprid 0.019 Sulfentrazone 17
doi:10.1371/journal.pone.0018540.t001
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which perturbed cardiomyocyte differentiation in ES cells per-
turbed multiple components involved in reactive oxygen species
signaling pathways in addition to critical developmental pathways.
Multivariate associations
In an effort to identify more complex patterns between the
ToxCast assay collection and cytotoxicity and/or differentiation in
our ES cell assay, machine learning algorithms were applied to
generate multivariate models that allowed us to develop
hypotheses for future testing. The predictors in the best model
of ES cell cytotoxicity comprise a collection of cell-based assays
that measured general cytotoxicity perturbations and decreased
immune system components (Figure 5A). This model had a
balanced accuracy of 0.78, indicating its strength. The top feature
that arose from the predictive model of ES cell cytotoxicity was the
Figure 3. ToxCast
TMPhase I chemical activity across cytotoxicity and differentiation ES cell assay endpoints. Heatmaps depict chemical
effectsoncytotoxicityanddifferentiationacrossdose.Unsupervised,two-dimensionalhierarchicalclusteringof320ToxCastchemicals across fourEScell
assayendpoints(cytotoxicityincrease,cytotoxicity decrease,differentiationincrease,differentiationdecrease)and4 doseseachusingEuclideandistance
for measure and Ward’s method for linkage analysis (A). Two-dimensional individual clusters for averaged dose normalized to controls for cytotoxicity
and differentiation endpoints (B). Heatmap scales represent relative activity based on AC50=2log10(M), ranging from 0 (white) to 2 (yellow).
doi:10.1371/journal.pone.0018540.g003
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response [28]. We also assessed the ability of the ToxCast assays to
generate a model which predicted decreased cardiomyocyte
differentiation in the ES cell assay. Although the predictive assays
for this model also included several measuring general cytotoxicity,
a significant feature was the gene expression-based assay for ATP-
binding cassette sub-family G member 2 (Abcg2) (Figure 5B).
Abcg2 is a xenobiotic half-transporter with wide substrate speci-
ficity and expression in multiple sites where protection from
toxicants is critical [29]. In addition, Abcg2 is highly expressed in
the Harderian gland [30], a chronic in vivo endpoint effect highly
correlated with decreased ES cell differentiation (Figure 4).
Discussion
ES cells are an attractive platform to assess developmental
toxicity because they are capable of recapitulating many of the
differentiation states and rely on signaling pathways present in
development. We used a mouse ES cell adherent cell differenti-
ation and cytotoxicity assay to assess the activity of a group of
chemicals (mainly pesticide active ingredients), most of which have
in vivo toxicity data. The results of this study demonstrated the
following: 1) a subset of tested chemicals were active in the ES cell
assay, 2) general cytotoxicity assays from the ToxCast program
were strongly associated with ES cell cytotoxicity assays, 3)
transcriptional activity assays were strongly associated with ES cell
differentiation assays, 4) statistical analysis identified predictive
models of increased ES cell cytotoxicity and decreased ES cell
differentiation for a subset of the tested chemicals.
This study examined the biological activity of 309 environmen-
tal chemicals in a mouse ES cell adherent cell differentiation and
cytotoxicity assay. The AC50 cutoff was used across the entire
ToxCast portfolio, therefore this was also the benchmark cutoff in
the ES cell assay. In addition, we selected the AC50 as an
appropriate level to determine the most potent developmental
toxicants. Based on the magnitude of effects, AC50 values were
calculated for 18% of the environmental chemicals tested. Because
the current study used the same plating library as other assays in
the ToxCast portfolio and because of the requirement to limit the
DMSO vehicle concentration, the present analysis was limited to
Figure 4. Associations between ToxCast
TM assays and ES cell endpoints. Univariate associations revealed multiple ToxCast assays correlate
with ES cell cytotoxicity and differentiation. ES cell cytotoxicity and differentiation correlated with limited in vivo endpoints in ToxRefDB.
doi:10.1371/journal.pone.0018540.g004
Figure 5. Multivariate models predict ES cell cytotoxicity and differentiation. ROC curves generated using data from ToxCast assays and ES
cells to drive machine learning algorithms that produced predictive models of ES cell cytotoxicity (A) and differentiation (B).
doi:10.1371/journal.pone.0018540.g005
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such, the results reported here focus on chemicals that were active
with AC50’s at these relatively low concentrations. Chemicals
that did not achieve a 50% change in cytotoxicity or cardiomy-
ocyte differentiation at the concentration range tested may be
biologically active, but not within this concentration range.
Additionally, because these studies were limited to an assessment
of cardiomyocyte differentiation, effects on ES cell differentiation
to other cell lineages may have been produced but not evaluated.
Other studies have shown a 30-fold change in chemical potency
when tested with two distinct ES cell lineage markers [31]. Finally,
many signaling pathways may be needed to fully evaluate
developmental toxicity in ES cells [32]. Expanding the endpoints
in our ES cell assay to monitor more diverse cell lineages and
signaling pathways as well as assessing alternative cutoff values
would be expected to identify a greater number of chemical
actives.
ToxCast enables the unique ability to correlate chemical effects
on the ES cell endpoints with a broader suite of ,500 assays. Such
an analyses revealed many novel relationships with ES cell
cytotoxicity based on their strong correlation for chemicals that
were active in human cell-based cytotoxicity assays. This bolsters
confidence in the use of the cytotoxicity assessment reported here
for evaluation of cytotoxicity between murine-human culture
models and seems to indicate that there are fundamental cellular
processes affected by these chemicals, rather than a developmen-
tally-specific response. Future studies to compare the concentra-
tion-dependent effects between adult and ES cells may identify
unique sensitivity in the ES cells. Additionally, evaluating chemical
agonists and antagonists of known developmental signaling targets
may be useful for determining the ability of the ES cell cytotoxicity
endpoint to identify perturbations in developmental signaling.
A group of transcriptional activity human cell-based assays
exhibited a strong association with decreased ES cell differentia-
tion. This association was specific to chemicals that produced a
50% decrease in cardiomyocyte marker expression, but not
chemicals that produced cytotoxicity. The developmental rele-
vance of several genes that associated with inhibition of
cardiomyocyte differentiation stands without question and fur-
thermore suggests this endpoint does, as anticipated, identify key
targets in mechanisms that are not detected by generic cytotoxic
response.
EachEScellendpointwascorrelatedwithadversedevelopmental
effectsinvivo.Inaddition,eachEScellendpoint correlatedtounique
developmental effects indicating the strength of using both
endpoints in future predictive models. However, the spectrum of
adverse developmental effects associated with perturbation of ES
cell endpoints was limited and effects on many organ systems were
not correlated. The limited correlation between in vivo and in vitro
surprising given the requirement of three independent assays to
Figure 6. Cartoon depicting chemical targets across multiple components of ROS signaling in ToxCast platforms. Chemicals that
decreased ES cell differentiation by at least 50% also targeted multiple components of ROS signaling. The statistical associations between decreased
ES cell differentiation and ToxCast assay platforms are highlighted (p#0.1).
doi:10.1371/journal.pone.0018540.g006
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concentration range evaluated, broadening the coverage of
differentiation states assessed, and integrating the differentiation
and cytotoxicity endpoints, we may expect to increase the ES cell
assay’s predictivity of in vivo toxicity. Further investigation into
chemicals that produced effects in vivo, but not in the ES cell assay
may provide valuable insight into species-specific toxicities and
allow us to define potential limitations of mouse ES cells in toxicity
testing. It is prudent to identify other assays that, in combination
with the ES cell platform, strengthen the predictive model for in vivo
associations.
The results reported here provide valuable information on the
potential pathway-level responses of ES cells. Univariate and
multivariate associations identified a collection of features that
predict decreased differentiation in ES cells. Many of these
features play a role in reactive oxygen species (ROS) signaling
(Figure 6). For instance, Oct1 has been identified as a critical
regulator of gene transcription during oxidative stress [33] and
knockout mutant mice showed hypersensitivity to oxidative stress
[34]. Bmpr2 is modulated under hypoxic conditions [35] and these
knockout mice are more susceptible to hypoxic pulmonary
hypertension [36]. Hif1a is responsive to oxidative stress [37,38]
and is required for maintenance of normal oxygen levels
throughout development [39]. Jun has been shown to associate
with Nrf2, an oxidative stress responder [40], and enhance
activation of the antioxidant response element (ARE), a binding
motif that plays a role in antioxidant gene regulation
[41,42,43,44,45,46]. Gsta2, an ARE-containing gene, exhibits
significantly reduced expression in Nrf2
2/2 mice [47]. The top
feature that predicted decreased ES cell differentiation, Abcg2,i s
also regulated by hypoxic conditions and contains multiple
putative AREs [48]. Abcg2 promoter constructs were mutated in
putative ARE sites and tested in vitro resulting in decreased
promoter activity suggesting functionality [48]. Furthermore,
electromobility shift assays indicated Hif1a, a transcription factor
assay highly associated with decreased ES cell differentiation
(Figure 4), binds to the ARE sequence proximal to Abcg2 [48]. In
the context of stem cells, Abcg2 is expressed in both mouse [49] and
human [50] ES cells as well as numerous tissue-specific stem cell
side populations [51]. Abcg2 expression is widely used as a marker
of stem cell populations, although its role in stem cells is not
entirely known [52]. Overexpression of Abcg2 inhibits differenti-
ation while lack of Abcg2 expression promotes differentiation of
stem cells [53]. Identification of Abcg2 as a target of Notch
signaling as well as its role in preserving stem cell pluripotency
suggests Abcg2 may function to maintain self-renewing stem cell
populations [53]. It would be interesting to assess gene expression
in the ES cell assay and determine whether: 1) Abcg2 is upregulated
upon exposure to the chemicals driving this predictive model, 2)
ES cells maintained in oxidative stress conditions mimic the gene
expression profile from chemical-treated ES cells, and 3) whether
ES cells exposed to this subset of chemicals exhibit stem-like
features.
Efforts continue towards using ToxCast and ES cell assays to
identify toxicity pathways and predict in vivo toxicity endpoints.
Towards this end, Phase II of ToxCast is underway with the
addition of approximately 700 chemicals including many com-
pounds with toxicity data from failed clinical trials as well as
chemicals used to assess the original EST.
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